A retrospective study evaluating clinical outcomes of patients with BRAFv⁶⁰⁰-mutated metastatic NSCLC (mNSCLC) receiving first-line (1L) dabrafenib-trametinib vs other standard of care in real-world practice
Latest Information Update: 24 Nov 2021
At a glance
- Drugs Dabrafenib (Primary) ; Trametinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 24 Nov 2021 New trial record